LOGIN  |  REGISTER
Recursion

Latest Financial Results & Earnings News

UnitedHealth Reports 2024 Results

January 16
Last Trade: 509.76 -0.83 -0.16

Revenues of $400.3 Billion Grew 8% Year-Over-Year Domestic Consumers Served by UnitedHealthcare Grew 2.1 Million Value-Based Care Patients Served by Optum Grew 600,000 Cash Flows from Operations were $24.2 Billion or 1.6x Net Income Full Year, Fourth Quarter Net Earnings were $15.51, $5.98 Per Share Full Year, Fourth Quarter Adjusted Net Earnings were $27.66, $6.81 Per Share Company Affirms 2025 Performance Outlook - / Jan 16,...Read more


Biomerica Reports Second Quarter Fiscal 2025 Financial Results

January 15
Last Trade: 0.64 -0.07 -9.35

Total Revenue Increases 5% Year-Over-Year Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2024. Key Highlights: Direct-to-Consumer...Read more


Walgreens Boots Alliance Reports Fiscal 2025 First Quarter Results

January 10
Last Trade: 12.45 -0.48 -3.71

Delivering Progress on Strategic Priorities; Maintaining Full Year Adjusted EPS Guidance First quarter financial results First quarter loss per share1 was $0.31 versus loss per share of $0.08 in the year-ago quarter. Loss per share in the current quarter includes costs related to the Footprint Optimization Program and an after-tax charge for fair value adjustments on variable prepaid forward derivatives related to the monetization of...Read more


Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

January 7
Last Trade: 29.92 0.08 0.27

Total revenue up 31% year-over-year primarily driven by strong software growth RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30,...Read more


Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

January 2
Last Trade: 6.48 0.04 0.62

Recorded Revenues of $32.6 Million for Q2 Fiscal 2025  Signed Multiple Development Agreements with New Customers  Strengthened Balance Sheet with Financing Raising Approximately $24.3 Million, and Favorable Restructuring of Credit Facility with BMO  Conference Call Today at 4:30pm ET CHASKA, Minn., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract...Read more


MedMira Reports First Quarter Results FY2025

December 31
Last Trade: 0.13 0.00 0.00

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress on its FDA application. At the same time, the Company achieved a number of regulatory...Read more


Jack Nathan Health Announces Its Q3 Fiscal 2025 Financial Results

December 30
Last Trade: 0.03 0.00 0.00

TORONTO / Dec 30, 2024 / Business Wire / Jack Nathan Medical Corp. (TSXV: JNH; OTCQB: JNHMF) (“Jack Nathan Health” or the “Company”) announced today its unaudited interim consolidated financial results for the third quarter of fiscal 2025, three and nine months ended October 31, 2024. Jack Nathan Health’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). Management Commentary Mike...Read more


Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

December 27
Last Trade: 2.23 0.04 1.83

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25 Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...Read more


Citius Pharmaceuticals Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

December 27
Last Trade: 1.06 0.00 0.00

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year...Read more


Citius Oncology Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

December 27
Last Trade: 1.06 0.00 0.00

CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and...Read more


Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

December 23
Last Trade: 9.21 -0.94 -9.26

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system...Read more


Devonian Health Reports First Quarter 2025 Financial Results and Grants Stock Options

December 23
Last Trade: 0.16 0.00 0.00

First quarter revenues increased by 360% year over year First quarter net loss for the quarter of $0.002 per share Grant of 1,535,715 stock options to independent directors QUEBEC CITY / Dec 23, 2024 / Business Wire / Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its first quarter ended on October 31, 2024. Management Comments “Devonian continued to improve...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE